Calamos Advisors’s BlackRock Health Sciences Trust BME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-14,619
Closed -$563K 1015
2026
Q1
$563K Sell
14,619
-11,401
-44% -$470K ﹤0.01% 894
2025
Q4
$1.07M Buy
26,020
+10,135
+64% +$400K ﹤0.01% 679
2025
Q3
$591K Buy
15,885
+10,121
+176% +$368K ﹤0.01% 755
2025
Q2
$210K Sell
5,764
-726
-11% -$26.3K ﹤0.01% 820
2025
Q1
$251K Buy
+6,490
New +$257K ﹤0.01% 784
2024
Q4
Sell
-5,188
Closed -$218K 916
2024
Q3
$218K Sell
5,188
-2,696
-34% -$112K ﹤0.01% 786
2024
Q2
$322K Buy
7,884
+2,500
+46% +$99.5K ﹤0.01% 739
2024
Q1
$223K Buy
+5,384
New +$225K ﹤0.01% 764

Other funds holding BME

Calamos Advisors's BME Position: Q2 2026 in Review

Calamos Advisors sold out of BlackRock Health Sciences Trust (BME) in Q2 2026, closing a stake of 14,619 shares — an estimated $563K sold.

Calamos Advisors first reported a position in BME in Q1 2024 and held it in 8 quarters. The position peaked at $1.07M in Q4 2025. 32 funds tracked by Wall St. Rank hold BME as of Q2 2026.

  • Calamos Advisors reported no remaining BlackRock Health Sciences Trust position as of Q2 2026 after selling out during the quarter.
  • Calamos Advisors sold 14,619 BlackRock Health Sciences Trust shares in Q2 2026, an estimated $563K.
  • Calamos Advisors first reported a position in BlackRock Health Sciences Trust in Q1 2024 and held it in 8 quarters.
  • Calamos Advisors's BlackRock Health Sciences Trust position peaked at $1.07M in Q4 2025.
  • 32 funds tracked by Wall St. Rank held BlackRock Health Sciences Trust as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.